Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Moderate-to-severe Psoriasis”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT02786186
What this trial is testing

A Registry of Patients With Moderate to Severe Plaque Psoriasis

Who this might be right for
Psoriasis
Novartis Pharmaceuticals 2,376
Not applicableStudy completedNCT01084668
What this trial is testing

Quality of Life in Adalimumab Treated Psoriasis Patients Failing Other Biologic Disease Modifying Anti-rheumatic Drugs

Who this might be right for
Psoriasis Chronic
Abbott 46
Large-scale testing (Phase 3)Study completedNCT01690299
What this trial is testing

Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis

Who this might be right for
PsoriasisPsoriatic Arthritis
Amgen 250
Not applicableStudy completedNCT05155098
What this trial is testing

2 Years Prospective Study to Collect Real-life Data on the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis

Who this might be right for
Moderate to Severe Plaque PsoriasisPsoriatic ArthritisAnkylosing Spondylitis+1 more
Novartis Pharmaceuticals 127
Post-approval studies (Phase 4)Ended earlyNCT02408159
What this trial is testing

Varicella Zoster Vaccine in Patients With Plaque Psoriasis Treated With Biologic Therapy

Who this might be right for
Psoriasis
Innovaderm Research Inc. 3
Post-approval studies (Phase 4)UnknownNCT03553433
What this trial is testing

Apremilast Treatment for Pruritus and Quality of Life in Scalp Psoriasis

Who this might be right for
Psoriasis of ScalpPsoriasis Vulgaris
University of Zurich 90
Post-approval studies (Phase 4)Study completedNCT02400749
What this trial is testing

Apremilast in Palmo-Plantar Psoriasis

Who this might be right for
Palmo-plantar Psoriasis
Innovaderm Research Inc. 100
Testing effectiveness (Phase 2)Study completedNCT05375955
What this trial is testing

Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.

Who this might be right for
Atopic DermatitisPlaque Psoriasis
Pfizer 263
Early research (Phase 1)Study completedNCT02397382
What this trial is testing

Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis

Who this might be right for
Psoriasis
Janssen Research & Development, LLC 16
Testing effectiveness (Phase 2)Study completedNCT02131324
What this trial is testing

DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis

Who this might be right for
Psoriasis
Promius Pharma, LLC 50
Not applicableEnded earlyNCT00402818
What this trial is testing

RESTORE: Raptiva® (Efalizumab) Evaluation of Safety and Treatment Optimization

Who this might be right for
Plaque Psoriasis
Merck KGaA, Darmstadt, Germany 294
Testing effectiveness (Phase 2)Study completedNCT05772520
What this trial is testing

The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis

Who this might be right for
Plaque Psoriasis
Hangzhou Highlightll Pharmaceutical Co., Ltd 82
Large-scale testing (Phase 3)Active Not RecruitingNCT06550076
What this trial is testing

TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Who this might be right for
Plaque Psoriasis
Takeda 2,099
Post-approval studies (Phase 4)Study completedNCT04306315
What this trial is testing

Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight

Who this might be right for
Psoriasis Vulgaris
LEO Pharma 385
Not applicableStudy completedNCT04398732
What this trial is testing

Study to Evaluate the Efficacy of Enbrel as a Biological Treatment in Moderate to Severe Plaque Psoriasis Patients

Who this might be right for
Plaque Psoriasis
Pfizer 486
Post-approval studies (Phase 4)UnknownNCT00707070
What this trial is testing

Combining Acitretin and Efalizumab in the Therapy of Chronic Plaque Psoriasis

Who this might be right for
Chronic Plaque Psoriasis
Universita di Verona 100
Testing effectiveness (Phase 2)Study completedNCT01045577
What this trial is testing

A Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Activity of Oral AB1010 in Adults Patients With Moderate to Severe Chronic Plaque Psoriasis

Who this might be right for
Psoriasis
AB Science 25
Not applicableStudy completedNCT00800982
What this trial is testing

Open Label Study Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque Type Psoriasis

Who this might be right for
Psoriasis
University of California, San Francisco 30
Testing effectiveness (Phase 2)Study completedNCT02785185
What this trial is testing

Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis

Who this might be right for
Psoriasis
Bausch Health Americas, Inc. 150
Testing effectiveness (Phase 2)Ended earlyNCT03329885
What this trial is testing

Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis

Who this might be right for
Rheumatoid ArthritisPsoriasisAnkylosing Spondylitis+2 more
Bristol-Myers Squibb 38
Next Page